Novartis’ Zolgensma experiences further safety issues
Novartis has announced the US Food and Drug Administration (FDA) has placed a partial hold on the company’s Phase I/II…
By
Diagnostic and testing
Latest in
Diagnostic and testing
Total prevalent cases of female infertility to decline to 13.4 million in 2028, says GlobalData
Infertility describes a difficulty in becoming pregnant after trying for a period of one year or more. Impaired feduncity is…
Alopecia Areata market set to be worth $1.7bn by 2028 driven by the launch of JAK inhibitors, says GlobalData
Alopecia Areata (AA) is a non-scarring form of alopecia which is also the second most common in the world. There…
By Global spinal muscular atrophy market set to reach US$6.6bn in 2028, says GlobalData
Spinal muscular atrophy (SMA) is a group of neurological disorders that cause a loss in muscle movement due to depleting…
Are M&As the Key to Securing Growth in the Orphan Drugs Sector?
The orphan drug market can be an alluringly lucrative sector. Most big pharma corporations inherit these specialty business units through mergers…
By
Restless Leg Syndrome sufferers not receiving accurate diagnosis
A significantly high proportion of the population in the West experiences restless leg symptoms, but less than one third receives…
ByPharma Technology Focus: Taming big pharma
In this issue: breakthroughs in HIV treatment, understanding drug-resistant TB, the fallout from Teva’s price fixing scandal, tackling unlicensed stem…
By
FDA approves Grifols’ Xembify for immunodeficiencies
Spanish plasma-derived medicine specialist Grifols has announced that the US Food and Drug Administration (FDA) has approved its Xembify (immune…
By